vimarsana.com
Home
Live Updates
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept "Tick-Kill" Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease -February 22, 2024 at 08:03 am EST : vimarsana.com
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept "Tick-Kill" Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease -February 22, 2024 at 08:03 am EST : vimarsana.com
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept "Tick-Kill" Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease -February 22, 2024 at 08:03 am EST
TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxisIRVINE, Calif., Feb. 22, 2024 -- Tarsus Pharmaceuticals,...
Related Keywords
United States ,
Americans ,
Adrienne Kemp ,
David Nakasone ,
Centers For Disease ,
Exchange Commission ,
Corporate Communications ,
Tarsus Pharmaceuticals Inc ,
Nasdaq ,
Disease Control ,
Tarsus Pharmaceuticals ,
Meibomian Gland Disease ,
Tarsu Form ,
Lyme Disease ,
Markets ,